{"result": {"id": "1deb91c2-e4b4-4d76-a5b3-c287fca5c9ad", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>THIJS L<|>PERSON<|>A researcher involved in cardiovascular protection and blood pressure reduction studies)\n##\n(\"entity\"<|>SYSTOLIC HYPERTENSION IN CHINA (SYST-CHINA)<|>EVENT<|>A clinical trial on isolated systolic hypertension in elderly Chinese patients)\n##\n(\"entity\"<|>CHINESE TRIAL ON ISOLATED SYSTOLIC HYPERTENSION IN THE ELDERLY<|>EVENT<|>Another name for the Syst-China trial)\n##\n(\"entity\"<|>BECKETT NS<|>PERSON<|>A researcher involved in hypertension treatment for elderly patients)\n##\n(\"entity\"<|>PETERS R<|>PERSON<|>A researcher involved in hypertension treatment for elderly patients)\n##\n(\"entity\"<|>FLETCHER AE<|>PERSON<|>A researcher involved in hypertension treatment for elderly patients)\n##\n(\"entity\"<|>PATEL A<|>PERSON<|>A researcher involved in the ADVANCE trial on diabetes and hypertension)\n##\n(\"entity\"<|>MACMAHON S<|>PERSON<|>A researcher involved in the ADVANCE trial on diabetes and hypertension)\n##\n(\"entity\"<|>THOMOPOULOS C<|>PERSON<|>A researcher involved in hypertension treatment studies)\n##\n(\"entity\"<|>BAZOUKIS G<|>PERSON<|>A researcher involved in hypertension treatment studies)\n##\n(\"entity\"<|>GRASSI G<|>PERSON<|>A researcher involved in hypertension treatment studies)\n##\n(\"entity\"<|>CHENGDU HYPERTENSION INTERVENTION TRIAL<|>EVENT<|>A Chinese trial studying nifedipine vs placebo for hypertension)\n##\n(\"entity\"<|>ZHANG TINGJIE<|>PERSON<|>A researcher involved in the Chengdu Hypertension Intervention Trial)\n##\n(\"entity\"<|>WANG Z<|>PERSON<|>A researcher involved in blood pressure reduction for stroke prevention)\n##\n(\"entity\"<|>LIU G<|>PERSON<|>A researcher involved in the FEVER study)\n##\n(\"relationship\"<|>STAESSEN JA<|>THIJS L<|>Collaborated on cardiovascular protection and blood pressure reduction studies<|>7)\n##\n(\"relationship\"<|>BECKETT NS<|>PETERS R<|>Collaborated on hypertension treatment for elderly patients<|>7)\n##\n(\"relationship\"<|>BECKETT NS<|>FLETCHER AE<|>Collaborated on hypertension treatment for elderly patients<|>7)\n##\n(\"relationship\"<|>PATEL A<|>MACMAHON S<|>Collaborated on the ADVANCE trial<|>7)\n##\n(\"relationship\"<|>THOMOPOULOS C<|>BAZOUKIS G<|>Collaborated on hypertension treatment studies<|>7)\n##\n(\"relationship\"<|>THOMOPOULOS C<|>GRASSI G<|>Collaborated on hypertension treatment studies<|>7)\n##\n(\"relationship\"<|>ZHANG TINGJIE<|>CHENGDU HYPERTENSION INTERVENTION TRIAL<|>Zhang Tingjie was involved in this trial<|>8)\n##\n(\"relationship\"<|>LIU L<|>WANG Z<|>Collaborated on blood pressure reduction for stroke prevention<|>7)\n##\n(\"relationship\"<|>LIU L<|>LIU G<|>Collaborated on the FEVER study<|>7)\n##\n(\"relationship\"<|>SYSTOLIC HYPERTENSION IN CHINA (SYST-CHINA)<|>CHINESE TRIAL ON ISOLATED SYSTOLIC HYPERTENSION IN THE ELDERLY<|>These refer to the same clinical trial<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558921, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 872, "prompt_tokens": 3817, "total_tokens": 4689, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3200}, "prompt_cache_hit_tokens": 3200, "prompt_cache_miss_tokens": 617}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: etal.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta- analysisofoutcometrials[J]. Lancet,2000,355(9207) :865-872.\n[216]  StaessenJA, WangJG, ThijsL.  Cardiovascularprotection and blood pressure reduction: a meta-analysis[J]. Lancet, 2001, 358\n(9290) :1305-1315.\n[217]  Wang JG, LiY, FranklinSS, et al.  Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview[J].  Hypertension, 2007, 50\n(1) :181-188.\n\n\n\n[218]  LiuL, WangJG, GongL, etal. Comparisonofactivetreatment and placebo in older Chinese patients with isolated systolic hy- pertension.  SystolicHypertensioninChina(Syst-China) Collab- orativeGroup[J]. J Hypertens,1998,16(12Pt1) :1823-1829.\n[219]  WangJG, StaessenJA, GongL, etal. Chinesetrialonisolated systolic hypertension in the elderly.   Systolic Hypertension in China(Syst-China) Collaborative Group[J]. Arch Intern Med,  2000,160(2) :211-220.\n[220]  GongL, ZhangW , Zhu Y, etal. Shanghaitrialofnifedipinein theelderly (STONE) [J]. J Hypertens, 1996, 14(10) : 1237- 1245.\n[221]  张廷杰 ,成都市高血压干预试验协作组.  高血压干预试验   硝苯  地平与安慰剂随机对照研究[J]. 中华心血管病杂志 , 1994, 22\n(3) :201-205.\n[222]  Liu L, ZhangY, Liu G, etal. TheFelodipineEventReduction (FEVER) study: arandomizedlong-term placebo-controlledtri- alin Chinese hypertensive patients[J]. J Hypertens, 2005, 23\n(12) :2157-2172.\n[223]  ZhangY, ZhangX, Liu L, etal. Effectsofindividualrisk fac- torson theresidualrisk ofcardiovasculareventsin a population of treated Chinese patients with hypertension:  data from  the FelodipineEventReduction (FEVER)  study[J]. J Hypertens,  2010,28(10) :2016-2025.\n[224]  Zhang Y, Zhang X, Liu L, et al.  Is a systolic blood pressure target<140mmHgindicatedinallhypertensives? Subgroupan- alyses of findings from the randomized FEVER trial[J]. Eur HeartJ,2011,32(12) :1500-1508.\n[225]  PATSCollaborating Group.  Post-stroke antihypertensive treat- mentstudy.  A preliminary result[J]. Chin MedJ (Engl) ,1995,  108(9) :710-717.\n[226]  Liu L, WangZ, GongL, etal. Bloodpressurereductionforthe secondaryprevention ofstroke: aChinesetrialand a systematic review oftheliterature[J]. Hypertens Res, 2009, 32(11) : 1032- 1040.\n[227]  PROGRESS Collaborative Group.  Randomised trialof a perin- dopril-basedblood-pressure-lowering regimen among6,105indi- viduals with previous stroke or transient ischaemic attack[J].   Lancet,2001,358(9287) :1033-1041.\n[228]  BeckettNS, PetersR, FletcherAE, etal. Treatmentofhyper- tension inpatients80 years ofage or older[J]. N EnglJ Med,  2008,358(18) :1887-1898.\n[229]  PatelA, ADVANCECollaborativeGroup, MacMahon S, etal.   Effectsofa fixed combination ofperindopriland indapamide on macrovascularand microvascularoutcomesinpatientswith type 2 diabetes mellitus (the ADVANCE trial) : a randomised con- trolledtrial[J]. Lancet,2007,370(9590) :829-840.\n[230]  刘力生 ,龚兰生 ,王文.  降压治疗对中国脑血管病患者脑卒中再 发预防的多中心随机双盲对照临床研究[J]. 中华心血管病杂 志 ,2005,33(7) :613-617.\n[231]  WorldHealthOrganization(WHO) .  Guidelineforthe pharma- cological treatment of hypertension in adults[ M].  Geneva:  WHO,2021:13.\n[232]  ThomopoulosC, BazoukisG, GrassiG, etal. Monotherapy vs combination treatmentsofdifferentcomplex\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>LANCET<|>ORGANIZATION<|>A medical journal that publishes research on hypertension and cardiovascular diseases)\n##\n(\"entity\"<|>STAESSEN JA<|>PERSON<|>A researcher involved in cardiovascular protection and blood pressure reduction studies)\n##\n(\"entity\"<|>WANG JG<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>LI Y<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>FRANKLIN SS<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>LIU L<|>PERSON<|>A researcher involved in hypertension and stroke prevention studies)\n##\n(\"entity\"<|>GONG L<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>ZHANG Y<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>ZHANG X<|>PERSON<|>A researcher involved in hypertension and cardiovascular studies)\n##\n(\"entity\"<|>SYSTOLIC HYPERTENSION IN CHINA (SYST-CHINA) COLLABORATIVE GROUP<|>ORGANIZATION<|>A research group focused on systolic hypertension in the elderly in China)\n##\n(\"entity\"<|>SHANGHAI TRIAL OF NIFEDIPINE IN THE ELDERLY (STONE)<|>EVENT<|>A clinical trial studying the effects of nifedipine in elderly hypertensive patients)\n##\n(\"entity\"<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>EVENT<|>A randomized long-term placebo-controlled trial in Chinese hypertensive patients)\n##\n(\"entity\"<|>POST-STROKE ANTIHYPERTENSIVE TREATMENT STUDY (PATS)<|>EVENT<|>A study on antihypertensive treatment after stroke)\n##\n(\"entity\"<|>PROGRESS COLLABORATIVE GROUP<|>ORGANIZATION<|>A group conducting trials on blood-pressure-lowering regimens in stroke patients)\n##\n(\"entity\"<|>ADVANCE COLLABORATIVE GROUP<|>ORGANIZATION<|>A group conducting trials on the effects of perindopril and indapamide in diabetic patients)\n##\n(\"entity\"<|>WORLD HEALTH ORGANIZATION (WHO)<|>ORGANIZATION<|>An international organization providing guidelines for the pharmacological treatment of hypertension)\n##\n(\"relationship\"<|>STAESSEN JA<|>WANG JG<|>Collaborated on cardiovascular protection and blood pressure reduction studies<|>7)\n##\n(\"relationship\"<|>WANG JG<|>LI Y<|>Collaborated on hypertension and cardiovascular studies<|>7)\n##\n(\"relationship\"<|>WANG JG<|>FRANKLIN SS<|>Collaborated on hypertension and cardiovascular studies<|>7)\n##\n(\"relationship\"<|>LIU L<|>GONG L<|>Collaborated on hypertension and stroke prevention studies<|>7)\n##\n(\"relationship\"<|>ZHANG Y<|>ZHANG X<|>Collaborated on hypertension and cardiovascular studies<|>7)\n##\n(\"relationship\"<|>SYSTOLIC HYPERTENSION IN CHINA (SYST-CHINA) COLLABORATIVE GROUP<|>WANG JG<|>Wang JG was part of the Syst-China Collaborative Group<|>8)\n##\n(\"relationship\"<|>FELODIPINE EVENT REDUCTION (FEVER) STUDY<|>LIU L<|>Liu L was involved in the FEVER study<|>8)\n##\n(\"relationship\"<|>POST-STROKE ANTIHYPERTENSIVE TREATMENT STUDY (PATS)<|>PROGRESS COLLABORATIVE GROUP<|>Both groups conducted studies on antihypertensive treatment post-stroke<|>6)\n##\n(\"relationship\"<|>ADVANCE COLLABORATIVE GROUP<|>WORLD HEALTH ORGANIZATION (WHO)<|>Both are involved in hypertension treatment research<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_647cd7250370d107af96a9960604b32e4795d90472fccff5422a8b89c806ccc4_v2"}